Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts.

From earnings beats to promising trial data and billion-dollar partnerships, investors are rewarding progress across oncology, immunology, and drug delivery platforms.

Here’s a quick look at four making the biggest move on Monday: CorMedix, RAPT Therapeutics, Celcuity, and Rani Therapeutics – and what’s driving their surge.

Here’s a look at four standout movers, CorMedix, Celcuity, Rani Therapeutics, and RAPT Therapeutics—and what’s driving their surge.

CorMedix Inc (NASDAQ: CRMD)

CorMedix stock is up nearly 10% in premarket on Monday after the biotech firm recorded strong quarterly earnings and raised its 2025 revenue guidance to $375 million.

This financial strength reflects growing momentum behind DefenCath®, its antimicrobial catheter lock solution recently approved by the FDA. With dialysis-related infections a persistent challenge, DefenCath’s market potential is rather significant.

The updated guidance signals confidence in commercial execution and scalability, giving investors a clearer path to profitability.

In a sector often defined by clinical risk, CRMD’s revenue visibility stands out. That’s partly why Wall Street currently rates this biotech stock at “buy” with a mean target that signals potential for another 85% upside from here.

Rani Therapeutics Holdings Inc (NASDAQ: RANI)

Rani Therapeutics shares are up another 30% this morning after announcing a billion-dollar deal with Chugai Pharmaceuticals – alongside a $60 million private placement.

The deal centers on Rani’s oral biologics delivery platform, including its flagship RaniPill capsule, which aims to replace injections with swallowable pills.

The announced agreement validates RANI’s tech and provides non-dilutive capital to accelerate development.

With chronic disease patients seeking alternatives to injections, Rani’s platform could reshape drug delivery – and investors are betting on that future. The only Wall Street firm that covers this biotech stock rates its at “buy”.  

Celcuity Inc (NASDAQ: CELC)

Celcuity stock is soaring today on news that it has completed enrollment for its Phase 3 trial evaluating gedatolisib in advanced breast cancer patients with PIK3CA mutations.

This milestone brings the company closer to pivotal data that could support regulatory approval.

Gedatolisib’s dual inhibition of PI3K and mTOR pathways positions it as a differentiated therapy in hormone receptor-positive, HER2-negative breast cancer – a large and underserved market.

Investors are responding to the clinical progress and the potential for CELC to emerge as a precision oncology leader. Wall Street also has a consensus “buy” rating on this biotech stock at the time of writing.

RAPT Therapeutics Inc (NASDAQ: RAPT)

RAPT Therapeutics’ stock is flying high after releasing positive Phase 2 results for RPT904 in chronic spontaneous urticaria.

The data showed meaningful symptom reduction and a favorable safety profile, validating the company’s approach to targeting immune pathways.

Chronic urticaria is a debilitating condition with limited treatment options – and RPT904’s performance could position it as a best-in-class therapy.

The results also reinforce the biotech’s broader immunology pipeline, boosting investor confidence in its platform and future trial readouts. Much like the other names on this list, RAPT stock is also “buy” rated among Wall Street firms in 2025.

The post CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why appeared first on Invezz